Synjardy
·
- Prescription status not stated
- Digestion, stomach, diabetes and nutrition
- Active substance
- Empagliflozin;metformin
- Made by
- Boehringer Ingelheim
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Synjardy is indicated in adults and children aged 10 years and above for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise: in patients insufficiently controlled on their maximally tolerated dose of metformin alone in combination with other medicinal products for the treatment of diabetes, in patients insufficiently controlled with metformin and these medicinal products in patients already being treated with the combination of empagliflozin and metformin as separate tablets. For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the population studied, see sections 4.4, 4.5 and 5.1.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
BulgariaNo exact match for this strength and form
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Boehringer Ingelheim |
|---|---|
| Active substance | Empagliflozin;metformin |
| Used in | Digestion, stomach, diabetes and nutrition |
| Classification | A10BD20 · Digestion, stomach, diabetes and nutrition |
| Authorised on | 2015-05-27 |
| Last updated by the regulator | 2026-08-06 |
| EMA product number | EMEA/H/C/003770 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).